The DeFACTO study

(Press-News.org) Munich, Germany – Data presented today from the prospective Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography (DeFACTO) study show that, when compared to standard coronary angiography (CT), the non-invasive assessment of fractional flow reserve by computed tomography (FFRct) provides a more accurate determination of which lesions require invasive evaluation.(1)

The results of the study were presented by Dr James K. Min, director of Cardiac Imaging Research and co-director of Cardiac Imaging at the Department of Medicine, Imaging and Biomedical Sciences at Cedars-Sinai Heart Institute in Los Angeles, USA.

The study compared the ability of FFRct and CT alone to identify flow-restricting lesions by assessment of fractional flow reserve, a measurement recognised as the gold standard for determining which lesions require treatment.(2) DeFACTO enrolled 252 stable patients with suspected coronary artery disease at 17 centres in five countries. All patients underwent CT, invasive coronary angiography, invasive FFR and subsequent FFRct analysis.

Results showed that FFRct was better able to identify flow-restricting arterial lesions than CT alone. The per-patient sensitivity and specificity of FFRct were also higher than CT alone using an area under the curve (AUC) analysis (AUC 0.81 vs. 0.68, p=0.0002).

The improvement in diagnostic performance was found greatest in arterial blockages of intermediate severity. In this set of patients, there was over a two-fold increase in test sensitivity, from 37 to 82%, with no loss of specificity. In these patients, the AUC improved from 0.53 for CT alone to 0.80 for FFRct (p=0.0002).

"One of the central challenges in taking care of patients with coronary artery disease is knowing which ones need further invasive evaluation for determining the need for coronary revascularization," said Dr Min. "The results of the DeFACTO trial clearly demonstrate that when added to coronary CT angiographic findings, FFRct provides essential physiologic information as to which specific arterial blockages truly restrict blood flow to the heart and heighten patient risk.

"This is an exciting step forward for cardiology that could significantly improve how we guide patients towards the most effective and efficient care. Our findings also suggest that FFRct could be particularly useful for evaluating patients with arterial blockages of an intermediate severity, which are often the most difficult to assess non-invasively. This represents a large group of patients who unfortunately are often prone to frequent misdiagnosis.

"In addition, given the high negative predictive value of FFRct, it may serve as an effective 'gatekeeper' to further unnecessary invasive procedures."

### References 1. The HeartFlow technology investigated in the study is a web-based service that enables the computation of non-invasive fractional flow reserve and thereby the identification of which lesions are causing ischemia. The technology computes FFRct from patient-specific 3D computational models of the aorta, heart and coronary artery tree obtained from CT scan data and results are transmitted via HeartFlow's secure web interface as an interactive report 2. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Guidelines on Myocardial Revascularization. Eur Heart J 2010; 31: 2501-255.

Notes to editors

Please note that the author's photo and CV as well as the spokesperson's CV can be found here

About the European Society of Cardiology www.escardio.org The European Society of Cardiology (ESC) represents more than 75,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.

About ESC Congress 2012 The ESC Congress is currently the world's premier conference on the science, management and prevention of cardiovascular disease. ESC Congress 2012 takes place 25-29 August at the Messe München in Munich. The scientific programme is available at: http://spo.escardio.org/Welcome.aspx?eevtid=54 More information is available from the ESC Press Office at press@escardio.org.